97183 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
HETERODIMERIC FC-FUSED PROTEINS
#302MODULATION OF DENDRITIC CELL LINEAGES
#303SINGLE DOMAIN ANTIBODIES AGAINST CLL-1
#304Site-specific antibody-drug conjugation through glycoengineering
#305MULTI-SPECIFIC BINDING PROTEINS THAT BIND BCMA, NKG2D AND CD16, AND METHODS OF USE
#306Methods of treating disorders associated with excess or unwanted killer cell lectin-like receptor subfamily g member 1 (KLRG1) expressing t cells with KLRG1 depleting antibodies
#307Galectin-7-specific monovalent antibodies and uses thereof
#308HETERODIMERIC FUSION PROTEIN
#309Targeting SARS-CoV-2 Viral-immune Interaction for COVID-19 Therapy
#310RADIOIMMUNOCONJUGATES AND DNA DAMAGE AND REPAIR INHIBITOR COMBINATION THERAPY
#311Actinium-225 and checkpoint inhibitor combination therapy
#312GLYCOENGINEERED ANTIBODY DRUG CONJUGATES
#313FUSION PROTEINS TARGETING TUMOUR ASSOCIATED MACROPHAGES FOR TREATING CANCER
#314NOVEL POLYPEPTIDES
#315IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE
#316CLEC12AxCD3 bispecific antibodies and methods for the treatment of disease
#317Anti-Gal3 antibodies and uses thereof
#318METHOD FOR PURIFYING ACTIVE POLYPEPTIDES OR IMMUNOCONJUGATES
#319METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
#320NK engager molecules and methods of use thereof
#321BIOLOGICAL PRODUCTS
#322CONJUGATED ANTIBOIDES AGAINST LY75 FOR THE TREATMENT OF CANCER
#323Methods of treating inflammatory diseases by blocking Galectin-3
#324Split inteins with exceptional splicing activity
#325PROTEIN BINDING NKG2D, CD16 AND A FIBROBLAST ACTIVATION PROTEIN
#326Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway
#327ANTIBODIES SPECIFIC FOR LOX1 AND USE IN TREATMENT OF CARDIOVASCULAR DISORDERS
#328ANTI-KLRG1 ANTIBODIES
#329LY75 AS CANCER THERAPEUTIC AND DIAGNOSTIC TARGET
#330Galectin-10 antibodies
#331USING C1 ESTERASE INHIBITOR TO TREAT VIRAL INFECTION-RELATED ACUTE RESPIRATORY DISTRESS
#332CLL1-TARGETING ANTIBODY AND APPLICATION THEREOF
#333Anti-galectin-9 antibody and methods of use thereof
#334ASPGR ANTIBODIES AND USES THEREOF
#335MULTI-SPECIFIC BINDING PROTEINS THAT BIND BCMA, NKG2D AND CD16, AND METHODS OF USE
#336Chimeric Antigen Receptor and Method for Treating Cancers
#337Methods and compositions for treating autoimmune and inflammatory conditions
#338PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
#339REGULATION OF TUMOR-ASSOCIATED T CELLS
#340Compositions and methods for targeted cytokine delivery
#341mRNA-mediated immunization methods
#342Single-domain antibodies against CLL1 and constructs thereof
#343Single-domain antibodies against CD33 and constructs thereof
#344METHOD FOR ACTIVATING IMMUNE RESPONSE OF TARGET CELL AND COMPOSITION THEREFOR
#345PROTEINS BINDING NKG2D, CD16, AND EGFR, CCR4, OR PD-L1
#346Nucleic acid sequencing using affinity reagents
#347PROTEINS BINDING NKG2D, CD16 AND P-CADHERIN
#348PROTEINS BINDING NKG2D, CD16 AND AN ANTIGEN ASSOCIATED WITH TUMORS, MDSCS AND/OR TAMS
#349MULTI-SPECIFIC BINDING PROTEINS AND IMPROVEMENTS THEREON
#350PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
#351Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of use
#352MULTISPECIFIC MOLECULES TARGETING CLL-1
#353METHOD FOR TREATMENT OF CANCER
#354Nucleic acid-polypeptide compositions and uses thereof
#355METHODS AND COMPOSITIONS FOR TARGETING LIVER AND LYMPH NODE SINUSOIDAL ENDOTHELIAL CELL C-TYPE LECTIN (LSECTIN)
#356DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS
#357Chimeric antigen receptor comprising third signal receptor and use thereof
#358ASGR INHIBITORS
#359COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
#360FC CONTAINING POLYPEPTIDES WITH ALTERED GLYCOSYLATION AND REDUCED EFFECTOR FUNCTION
#361TREATMENT OF CANCER USING A CD33 CHIMERIC ANTIGEN RECEPTOR
#362BISPECIFIC SIGNALING AGENTS AND USES THEREOF
#363TARGETING THE M2-TUMOR ASSOCIATED MACROPHAGE FOR CANCER THERAPY
#364MULTISPECIFIC BINDING PROTEINS TARGETING CAIX, ANO1, MESOTHELIN, TROP2, OR CLAUDIN-18.2
#365TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF
#366Anti-inflammatory polypeptides
#367PROTEINS BINDING CD33, NKG2D AND CD16
#368Monoclonal antibodies that bind human CD161
#369Multispecific antigen-binding molecules binding to a target and an internalizing effector protein that is CD63 and uses thereof
#370Glycan-dependent immunotherapeutic molecules
#371Pharmaceutical combinations
#372ENGINEERED THERAPEUTIC TO ENHANCE CYTOTOXIC ACTIVITY AND PHAGOCYTOSIS IN TUMOR ASSOCIATED MACROPHAGES
#373RNAi constructs for inhibiting ASGR1 expression and methods of use thereof
#374Antibody which is Directed Against Galectin-9 and is an Inhibitor of the Suppressor Activity of Regulatory T Lymphocytes
#375ANTI-GALECTIN ANTIBODY BIOMARKERS PREDICTIVE OF ANTI-IMMUNE CHECKPOINT AND ANTI-ANGIOGENESIS RESPONSES
#376Anti-inflammatory polypeptides
#377Mosaic chimeric viral vaccine particle
#378Anti-galectin-1 (Gal1) monoclonal antibodies and fragments thereof for neutralizing Gal1
#379BISPECIFIC ANTIBODY CAR CELL IMMUNOTHERAPY
#380COMBINATION THERAPY OF CANCER INVOLVING MULTI-SPECIFIC BINDING PROTEINS THAT ACTIVATE NATURAL KILLER CELLS
#381Specific binding molecule directed against galectin-3 protein
#382METHODS AND COMPOSITIONS FOR TREATING HYPERPIGMENTATION DISORDERS
#383Inhibitors of the interaction between CLEC14A and multimerin-2 for inhibition of angiogenesis
#384Antibody variable domains targeting the NKG2D receptor
#385PLZF+ REGULATORY CD8 T CELLS FOR CONTROL OF INFLAMMATION
#386DENDRITIC CELL IMMUNORECEPTOR AGONIST
#387Antibodies to galectin-3 and methods of use thereof
#388Antibodies binding to NKG2D
#389COMBINED INHIBITION OF SEMAPHORIN-4D AND TGF-BETA AND COMPOSITIONS THEREFOR
#390Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
#391Clec9A binding agents comprising a recombinant heavy-chain only antibody (VHH)
#392BI-FUNCTIONAL PROTEINS AND CONSTRUCTION THEREOF
#393METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
#394METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
#395KLRG1 Binding Compositions and Methods of Use Thereof
#396USE OF BISPECIFIC ANTIBODY AND IL-15 FOR COMBINATION THERAPY
#397ANTIBODY VARIABLE DOMAINS TARGETING CD33, AND USE THEREOF
#398CELLULAR BASED THERAPIES TARGETING DISEASE-ASSOCIATED MOLECULAR MEDIATORS OF FIBROTIC, INFLAMMATORY AND AUTOIMMUNE CONDITIONS
#399CHIKV RNA vaccines
#400ZIKA VIRUS MRNA VACCINES
#401CROSS-SPECIES-SPECIFIC PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALINXCD3, EPCAMXCD3, IGF-1RXCD3 OR FAPALPHAXCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
#402SINGLE-CHAIN MULTIVALENT BINDING PROTEINS WITH EFFECTOR FUNCTION
#403Chimeric antigen receptor specific for BDCA2 antigen
#404CLEC12a binding polypeptides and uses thereof
#405DENDRITIC CELLS-TARGETING VACCINE
#406CD33-binding polypeptides and uses thereof
#407Gene therapy for eosinophilic disorders
#408Killer cell lectin-like receptor subfamily G member 1 (KLRG1) depleting antibodies
#409MULTISPECIFIC ANTIGEN BINDING PROTEINS
#410Therapeutic interferon alpha 1 proteins
#411Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
#412Antibodies that bind to c-type lectin domain family 2 member d (CLEC2D)
#413Use of an antibody specific for BDCA 2 for ligation and removal of dendritic cells in the treatment systemic lupus erythematosis
#414Antibody-drug conjugate
#415Anti-CD303 Monoclonal Antibodies
#416PROTEINS BINDING NKG2D, CD16, AND C-TYPE LECTIN-LIKE MOLECULE-1 (CLL-1)
#417PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
#418Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
#419Formulations of antibody molecules to dengue virus
#420PROTEINS BINDING GD2, NKG2D AND CD16
#421Method for purifying active polypeptides or immunoconjugates
#422PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
#423Proteins binding HER2, NKG2D and CD16
#424Preparation of therapeutic exosomes using membrane proteins
#425PROTEINS BINDING NKG2D, CD16, AND EGFR, HLA-E, CCR4, OR PD-L1
#426TREATMENT OF CANCER USING A CLL-1 CHIMERIC ANTIGEN RECEPTOR
#427OPTIMIZING DIAGNOSTICS FOR GALACTOFURANOSE CONTAINING ANTIGENS
#428Anti-human CD69 antibody, and use thereof for medical purposes
#429Yeast-Based Immunotherapy for Tumour Prevention
#430Methods for detecting sinusoidal obstructive syndrome (SOS)
#431Phenotypic profiling of hepatocellular carcinoma circulating tumor cells for treatment selection
#432METHODS AND COMPOSITIONS FOR TREATING SYSTEMIC MASTOCYTOSIS
#433PROTEINS BINDING NKG2D, CD16 AND FLT3
#434Peptidomimetic compounds and antibody-drug conjugates thereof
#435PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
#436PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
#437Antibody molecules which bind CD22
#438Anti-CLL-1 antibodies and methods of use
#439Hyperglycosylated binding polypeptides
#440Methods and Compositions for Dectin-2 Stimulation and Cancer Immunotherapy
#441NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
#442METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASES OR CONDITIONS
#443Insulin immunoglobulin fusion proteins
#444CHIMERIC RECEPTORS AND METHODS OF USE THEREOF
#445Anti-galectin-7 antibody, kit comprising the same, and uses thereof
#446Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
#447Selective elimination of erosive cells
#448ASPGR antibodies and uses thereof
#449Deimmunized Serum-Binding Domains and Their Use in Extending Serum Half-Life
#450ANTIBODY HEAVY CHAIN VARIABLE DOMAINS TARGETING THE NKG2D RECEPTOR
#451COMBINATION OF ANT-CD303 AND ANTI-AMHRII ANTIBODIES
#452Mosaic chimeric viral vaccine particle
#453Inhibitors of prototypic galectin dimerization and uses thereof
#454METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
#455METHODS AND COMPOSITIONS OF TREATING AUTOIMMUNE DISEASES
#456Methods of activating CD32b/c comprising administering an antibody that binds BDCA-2 (CD303)
#457Composition for treating fulminant acute pneumonia including CD69 antagonist
#458Split inteins with exceptional splicing activity
#459METHODS AND COMPOSITION FOR INHIBITING TUMOR GROWTH AND ENHANCING IMMUNE RESPONSES TO TUMORS
#460TUMOR ANTIGEN PRESENTATION INDUCER CONSTRUCTS AND USES THEREOF
#461Tissue-specific Wnt signal enhancing molecules and uses thereof
#462Pharmaceutical combinations comprising an anti-LY75 antibody
#463Antibodies Against Human NKG2D and Uses Thereof
#464Methods of treating or alleviating joint diseases by administering an inhibitor of discoidin domain receptor 1 (DDR1)
#465PROTEINS BINDING PSMA, NKG2D AND CD16
#466Methods for modulating angiogenesis of cancers refractory to anti-VEGF treatment
#467Galectin-10 antibodies
#468Bispecific signaling agents and uses thereof
#469Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer
#470Clec9A binding agents
#471Multivalent antibody
#472ANTIBODY SPECIFIC FOR CD22 AND METHODS OF USE THEREOF
#473Bispecific IgG antibodies as T cell engagers
#474Phage conjugates and uses thereof
#475ANTI-ATHEROSCLEROTIC AGENT AND SYMPTOM IDENTIFICATION METHOD FOR ARTERIOSCLEROSIS
#476CHIMERIC ANTIGEN RECEPTOR AND NATURAL KILLER CELLS EXPRESSING SAME
#477COMBINATION OF ANTI-CD303 AND ANTI-HER2 ANTIBODIES
#478METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
#479Methods for the identification, targeting and isolation of human dendritic cell (DC) precursors “pre-DC” and their uses thereof
#480LY75 AS CANCER THERAPEUTIC AND DIAGNOSTIC TARGET
#481Targeting agent antibody conjugates and uses thereof
#482METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
#483RNAi constructs for inhibiting ASGR1 expression and methods of use thereof
#484Methods for promoting t cells response by administering an antagonist of human c-type lectin-like receptor 1 (CLEC-1)
#485DEGLYCOSYLATED ANTIBODY SPECIFICALLY BINDING TO CLEC14A AND USES THEREOF
#486MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF
#487ENGINEERED LYMPHOCYTES
#488Inhibitory Immune Receptor Inhibition Methods and Compositions
#489Modified A1-A2 domains of non-natural NKG2D ligands that bind non-natural NKG2D receptors
#490Method for Predicting the Response of a Subject with an Autoimmune Disease to a B Cell-Targeting Therapy
#491Methods of Treating Crohn's Disease with an Anti-NKG2D Antibody
#492KLRG1 antagonist signaling therapy
#493COMPOSITIONS AND METHODS FOR T-CELL AND CYTOKINE ACTIVATION
#494Modulation of Type I Interferons to Reactivate HIV-1 Reservoir and Enhance HIV-1 Treatment
#495PHARMACEUTICAL COMPOSITIONS AND DOSAGE REGIMENS FOR CLINICAL USE OF ANTI-BLOOD DENDRITIC CELL ANTIGEN 2 ANTIBODIES
#496Antibodies specific for LOX1 and use in treatment of cardiovascular disorders
#497CD33 BINDING AGENTS
#498Anti-human BDCA-2 antibody
#499Anti-CLL-1 antibodies and immunoconjugates
#500Methods of treating cardiovascular disease with an anti-ASGR antibody or binding fragments thereof
#501ANTI-NKG2A ANTIBODIES AND USES THEREOF
#502Site-specific antibody-drug conjugation through glycoengineering
#503ANTI-HUMAN CD69 ANTIBODY, AND USE THEREOF FOR MEDICAL PURPOSES
#504Human CD3 binding antibody
#505TREATMENT OF ACUTE LIVER FAILURE
#506Cys80 conjugated immunoglobulins
#507IMPROVED PHARMACOKINETIC ASSAYS FOR IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
#508KLRG1 DEPLETION THERAPY
#509Anti-TEM1 antibodies and uses thereof
#510Immunoconjugates with an intracellularly-cleavable linkage
#511Optimized PNE-based chimeric receptor T cell switches and uses thereof
#512Endosialin-binding antibody
#513Methods of Treating Sickle Cell Disease
#514Anti-IgE antibodies
#515Depletion of plasmacytoid dendritic cells
#516MONOCLONAL ANTIBODIES AGAINST NKG2A
#517GALECTIN IMMUNOTHERAPY
#518Anti-galectin-1 (GAL1) monoclonal antibodies and fragments thereof for neutralizing GAL1
#519Compositions and methods for targeted cytokine delivery
#520MODULAR NANODEVICES FOR SMART ADAPTABLE VACCINES
#521Preparation of therapeutic exosomes using membrane proteins
#522CONJUGATED ANTIBODIES AGAINST LY75 FOR THE TREATMENT OF CANCER
#523Methods Of Identifying Anti-Inflammatory Compounds
#524KLRG1 SIGNALING THERAPY
#525Antibodies and related molecules and uses thereof
#526CHIMERIC ANTIGEN RECEPTOR
#527Peptidomimetic compounds and antibody-drug conjugates thereof
#528IMMUNE-CHECKPOINT INHIBITORS FOR USE IN THE TREATMENT OF BLOOD-BORNE CANCERS
#529Compositions and methods for activation of NK cells killing of prostate cancer and breast cancer cells
#530CD8 binding agents
#531Nucleic acid-polypeptide compositions and uses thereof
#532Nucleic acid-polypeptide compositions and uses thereof
#533Preparation of therapeutic exosomes using membrane proteins
#534Glycoengineered antibody drug conjugates
#535Infectious disease vaccines
#536BISPECIFIC SINGLE CHAIN ANTIBODIES WITH SPECIFICITY FOR HIGH MOLECULAR WEIGHT TARGET ANTIGENS
#537Nucleic acids encoding lectin-like oxidized LDL receptor 1 antibodies
#538ASPGR ANTIBODIES AND USES THEREOF
#539Fusion proteins targeting tumour associated macrophages for treating cancer
#540Insulin immunoglobulin fusion proteins
#541METHODS AND COMPOSITIONS FOR DECTIN-2 STIMULATION AND CANCER IMMUNOTHERAPY
#542Antibody-drug conjugate
#543NEW USE OF AN ANTI-CD303 TRANSMEMBRANE PROTEIN ANTIBODY
#544Deimmunized Serum-Binding Domains and Their Use in Extending Serum Half-Life
#545Method for purifying active polypeptides or immunoconjugates
#546NKG2D decoys
#547ANTI-BLOOD DENDRITIC CELL ANTIGEN 2 ANTIBODIES AND USES THEREOF
#548PYRROLOBENZODIAZEPINES AND ANTIBODY DISULFIDE CONJUGATES THEREOF
#549Humanized anti-CLL-1 antibodies
#550CHIKV RNA vaccines
#551ANTI- NKG2D SINGLE DOMAIN ANTIBODIES AND USES THEREOF
#552MULTISPECIFIC IMMUNOMODULATORY ANTIGEN-BINDING CONSTRUCTS
#553CYSTEINE-SUBSTITUTED IMMUNOGLOBULINS
#554Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
#555Nucleic acids encoding chimeric and humanized anti-histone antibodies
#556Inhibitors of the interaction between CLEC14A and multimerin-2 for inhibition of angiogenesis
#557Isoquinolidinobenzodiazepines
#558Zika RNA vaccines
#559Antibodies specific for CLL-1
#560OMALIZUMAB RESISTANT IGE VARIANTS AND THEIR USE IN ANTI-IGE THERAPY
#561Antibody molecules which bind CD22
#562Compositions and methods for inhibiting cancer stem cells
#563TARGETING THE M2-TUMOR ASSOCIATED MACROPHAGE FOR CANCER THERAPY
#564Methods for the Modulation of LGALS3BP to Treat Systemic Lupus Erythematosus
#565Human CD3 binding antibody
#566Bivalent antibody directed against NKG2D and tumor associated antigens
#567Nucleic acid sequencing using affinity reagents
#568METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
#569METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
#570GPC3 and ASGPR1 double-targeted transgenic immune effector cell and use thereof
#571Methods and agents for treating Alzheimer's disease
#572Anti-inflammatory polypeptides
#573Chimeric and humanized anti-histone antibodies
#574Glycan-dependent immunotherapeutic molecules
#575Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
#576Subcutaneous anti-HLA-DR monoclonal antibody for treatment of hematologic malignancies
#577Inhibitors of prototypic galectin dimerization and uses thereof
#578ASPGR antibodies and uses thereof
#579SINGLE-CHAIN MULTIVALENT BINDING PROTEINS WITH EFFECTOR FUNCTION
#580RECOMBINANT PRODUCTION OF MIXTURES OF ANTIBODIES
#581Antibodies against human NKG2D and uses thereof
#582OPTIMIZED CHIMERIC RECEPTOR T CELL SWITCHES AND USES THEREOF
#583Fc containing polypeptides with altered glycosylation and reduced effector function
#584RECOMBINANT PRODUCTION OF MIXTURES OF ANTIBODIES
#585COMPOSITIONS AND METHODS FOR PREVENTING TUMOR GROWTH AND TREATING CANCER BY TARGETING LECTIN GALACTOSIDE-BINDING SOLUBLE 3 BINDING PROTEIN
#586Mosaic chimeric viral vaccine particle
#587ANTI-CD22 ANTIBODIES
#588Anti-CD303 monoclonal antibodies
#589Anti-MICA antigen binding fragments, fusion molecules, cells which express and methods of using
#590Trispecific binding molecules for treating HBV infection and associated conditions
#591Cell line overexpressing human CD303 antigen
#592Anti-inflammatory polypeptides
#593Treatment of cancer using a CD33 chimeric antigen receptor
#594TREATING SOLID TUMOR BY TARGETING DECTIN-1 SIGNALING
#595Anti-CLL-1 antibodies and immunoconjugates
#596Anti-CLL-1 antibodies and immunoconjugates
#597COMPOUNDS FOR IMPROVING THE HALF-LIFE OF VON WILLEBRAND FACTOR
#598Antibody targeting osteoclast-related protein Siglec-15
#599Methods for treating ischemic stroke using chimeric and humanized anti-histone antibodies
#600SOLUBLE MIC NEUTRALIZING MONOCLONAL ANTIBODY FOR TREATING CANCER